1、White PaperCo-creating a New Health EcosystemHow rethinking product strategy can transform patient outcomes,drive system readiness,and improve commercial performanceCRISTINA ALZAGA-CHAUDHRY,EMEA Lead,Commercial Strategy&Transformation,IQVIA BRIAN NEEDHAM,Associate Principal,Strategy Consulting,IQVIA

2、Table of contentsExecutive summary 11.Introduction:A crossroads for healthcare and life sciences companies 32.Map to understand the disease area 63.Model to prioritize win-win-win opportunities 84.Act to co-create mutual value 105.Benefits and next steps 12References 14Acknowledgements 15 |1Health s

3、ystems are under unprecedented strain demand for better outcomes is rising,yet costs continue to climb.To stay ahead,life sciences companies must evolve from drug developers to partners in healthcare transformation.A new question arises:How might the life sciences industry elevate its stature as a s

4、trategic partner by playing a more prominent role in mapping,modelling,and acting on opportunities to transform care?This whitepaper introduces IQVIAs Map,Model,Act framework to help life sciences companies redefine their approach to asset,brand,and disease area strategy with a starting point in the

5、 market versus the traditional emphasis on product profiles and brand benefits.Done well,this elevates the companys role in healthcare,enhances collaboration with health systems,and drives sustainable patient,health system,and business impact.Executive summary2|Co-creating a New Health EcosystemThro

6、ugh three core pillars,the Map,Model,Act framework enables life sciences companies to:Map the disease landscape and related patient journeys to better pinpoint actionable unmet needs and care gaps.Model tangible strategies that reconcile health system priorities and company objectives.Act through ta